MyVax Personalized Immunotherapy: Additional Phase II data

Long-term follow-up data for a median of 5.8 years from an open-label, U.S. Phase II trial in 21 evaluable patients showed an increase in time to disease progression with MyVax after chemotherapy vs. ...